Haemonetics (NYSE:HAE) Receives “Hold” Rating from Needham & Company LLC

Haemonetics (NYSE:HAE)‘s stock had its “hold” rating restated by analysts at Needham & Company LLC in a research note issued on Friday, Benzinga reports.

Several other equities research analysts have also recently commented on HAE. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Barrington Research restated an “outperform” rating and issued a $105.00 price target on shares of Haemonetics in a research report on Friday, April 12th. Finally, TheStreet lowered shares of Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Three investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $104.67.

Haemonetics Stock Performance

HAE opened at $92.59 on Friday. Haemonetics has a twelve month low of $70.74 and a twelve month high of $97.13. The stock has a market cap of $4.70 billion, a PE ratio of 37.64, a price-to-earnings-growth ratio of 2.23 and a beta of 0.34. The business’s 50 day moving average is $83.98 and its 200-day moving average is $82.88. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, topping the consensus estimate of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The firm had revenue of $336.20 million for the quarter, compared to analysts’ expectations of $320.84 million. During the same quarter in the previous year, the company earned $0.85 earnings per share. The firm’s quarterly revenue was up 10.1% compared to the same quarter last year. On average, analysts predict that Haemonetics will post 3.95 earnings per share for the current year.

Insider Buying and Selling at Haemonetics

In other news, EVP Anila Lingamneni sold 2,305 shares of the business’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $95.00, for a total transaction of $218,975.00. Following the transaction, the executive vice president now directly owns 12,295 shares in the company, valued at approximately $1,168,025. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 1.79% of the company’s stock.

Institutional Trading of Haemonetics

A number of institutional investors have recently added to or reduced their stakes in HAE. Carmel Capital Partners LLC bought a new position in shares of Haemonetics during the 3rd quarter valued at $30,000. TFO Wealth Partners LLC raised its holdings in shares of Haemonetics by 29,450.0% during the 4th quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 589 shares in the last quarter. Group One Trading L.P. bought a new position in shares of Haemonetics during the 3rd quarter valued at $55,000. Parkside Financial Bank & Trust raised its holdings in shares of Haemonetics by 17.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock valued at $90,000 after purchasing an additional 156 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Haemonetics during the 1st quarter valued at $114,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.